Van der Heijde D, Dougados M, Davis J, et al.: Assessment in Ankylosing Spondylitis International Working Group/ Spondylitis Association of America recommendations for conducting clinical trials in ankylosing spondylitis. Arthritis Rheum 2005, 52:386–394. ArticlePubMed Google Scholar
Biomarkers Definitions Working Group: Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin Pharmacol Ther 2001, 69:89–95. Article Google Scholar
Pages F, Berger A, Camus M, et al.: Effector memory T cells, early metastasis, and survival in colorectal cancer. N Engl J Med 2005, 353:2654–2666. ArticlePubMedCAS Google Scholar
Braun J, Bollow M, Neure L, et al.: Use of immunohistologic and in situ hybridization techniques in the examination of sacroiliac joint biopsy specimens from patients with ankylosing spondylitis. Arthritis Rheum 1995, 38:499–505. ArticlePubMedCAS Google Scholar
De Rycke L, Vandooren B, Kruithof E, et al.: Tumor necrosis factor alpha blockade treatment down-modulates the increased systemic and local expression of Toll-like receptor 2 and Toll-like receptor 4 in spondylarthropathy. Arthritis Rheum 2005, 52:2146–2158. ArticleCAS Google Scholar
Zhang X, Glogauer M, Zhu F, et al.: Innate immunity and arthritis: neutrophil Rac and toll-like receptor 4 expression define outcomes in infection-triggered arthritis. Arthritis Rheum 2005, 52:1297–1304. ArticlePubMedCAS Google Scholar
Kim TH, Stone M, Payne U, et al.: Cartilage biomarkers in ankylosing spondylitis: relationship to clinical variables and treatment response. Arthritis Rheum 2005, 52:885–891. This study analyzes the profile of serum markers of cartilage breakdown in patients with AS. ArticlePubMedCAS Google Scholar
Smith GW, James V, Mackenzie DA, et al.: Ankylosing spondylitis and secretor status: a re-evaluation. Br J Rheumatol 1997, 36:778–780. ArticlePubMedCAS Google Scholar
Spoorenberg A, van der Heijde D, de Klerk E, et al.: Relative value of erythrocyte sedimentation rate and C-reactive protein in assessments of disease activity in ankylosing spondylitis. J Rheumatol 1999, 26:980–984. PubMedCAS Google Scholar
Rudwaleit M, Listing J, Brandt J, et al.: Prediction of a major clinical response (BASDAI 50) to tumour necrosis factor alpha blockers in ankylosing spondylitis. Ann Rheum Dis 2004, 63:665–670. ArticlePubMedCAS Google Scholar
Ruof J, Stucki G: Validity aspects of erythrocyte sedimentation rate and C-reactive protein in ankylosing spondylitis: a literature review. J Rheumatol 1999, 26:966–970. PubMedCAS Google Scholar
Vandooren B, Kruithof E, Yu DT, et al.: Involvement of matrix metalloproteinases and their inhibitors in peripheral synovitis and down-regulation by tumor necrosis factor alpha blockade in spondylarthropathy. Arthritis Rheum 2004, 50:2942–2953. ArticlePubMedCAS Google Scholar
Yang C, Gu J, Rihl M, et al.: Serum levels of matrix metalloproteinase 3 and macrophage colony-stimulating factor 1 correlate with disease activity in ankylosing spondylitis. Arthritis Rheum 2004, 51:691–699. ArticlePubMedCAS Google Scholar
Chen CH, Lin KC, Yu DT, et al.: Serum matrix metalloproteinases and tissue inhibitors of metalloproteinases in ankylosing spondylitis: MMP-3 is a reproducibly sensitive and specific biomarker of disease activity. Rheumatology 2006, 45:414–420. This study provides evidence that serum levels of MMP-3 can reflect the activity of disease in AS. ArticlePubMedCAS Google Scholar
Stone MA, Payne U, Pacheco-Tena C, Inman RD: Cytokine correlates of clinical response patterns to infliximab treatment of ankylosing spondylitis. Ann Rheum Dis 2004, 63:84–87. ArticlePubMedCAS Google Scholar
Poole AR: Biochemical/immunochemical biomarkers of osteoarthritis utility for prediction of incident or progressive osteoarthritis. Rheum Dis Clin North Am 2003, 29:803–818. ArticlePubMed Google Scholar
Billinghurst RC, Dahlberg L, Ionescu M, et al.: Enhanced cleavage of type II collagen by collagenases in osteoarthritic articular cartilage. J Clin Invest 1997, 99:1534–1545. PubMedCAS Google Scholar
Kojima T, Mwale F, Yasuda T, et al.: Early degradation of type IX and type II collagen with the onset of experimental inflammatory arthritis. Arthritis Rheum 2001, 44:120–127. ArticlePubMedCAS Google Scholar
Nelson F, Dahlberg L, Laverty S, et al.: Evidence for altered synthesis of type II collagen in patients with osteoarthritis. J Clin Invest 1998, 102:2115–2125. ArticlePubMedCAS Google Scholar
Poole AR: Cartilage in health and disease. In Arthritis and Allied Conditions: A Textbook of Rheumatology, edn 14. Edited by Koopman WJ. Philadelphia: Lippincott Williams & Wilkins; 2001:226–284. Google Scholar
Poole AR, Howell DS: Etiopathogenesis of osteoarthritis. In Osteoarthritis: Diagnosis and Medical/Surgical Management, edn 3. Edited by Moskowitz RW, Howell DS, Goldberg VM, et al.: Baltimore: WB Saunders Co.; 2001:29–47. Google Scholar
Maksymowych WP, Poole AR, Hiebert L, et al.: Etanercept exerts beneficial effects on articular cartilage biomarkers of degradation and turnover in patients with ankylosing spondylitis. J Rheumatol 2005, 32:1911–1917. This study addresses the effect of etanercept in AS with respect to serum markers of cartilage breakdown. PubMedCAS Google Scholar
Baeten D, Moller HJ, Delanghe J, et al.: Association of CD163+ macrophages and local production of soluble CD163 with decreased lymphocyte activation in spondylarthropathy synovitis. Arthritis Rheum 2004, 50:1611–1623. ArticlePubMed Google Scholar
Kruithof E, De Rycke L, Roth J, et al.: Immunomodulatory effects of etanercept on peripheral joint synovitis in the spondylarthropathies. Arthritis Rheum 2005, 52:3898–3909. The immunopathology of synovial tissues in SpA is shedding light on current concepts of pathogenesis and providing insights into new therapeutic targets. ArticlePubMedCAS Google Scholar